Haemonetics (HAE) reported earnings for the first quarter of fiscal 2010 of $0.69 diluted earnings per share, a 17% increase from $0.59 1Q09 diluted earnings per share, and beating Bloomberg analysts’ estimate by 6%. HAE also pulled strong margin improvement, adding 370 basis points to operation income margin of 17.1%.
The largest component of Haemonetics business, plasma disposables, showed some nice growth for the quarter, marking a 26% increase in $154 million revenue, benefiting from long term contract implementations, global growth in plasma collections, and price increases. Platelet disposables revenue was $34 million for the quarter, down 4% and Red Cell Disposables revenue was $12 million, leveling with previous year over year.
The company reiterated its full year earnings per share guidance at $2.75 to $2.85.
With all this positive news on Haemonetics earnings, stock still closed 5.1% lower for the day.
Tuesday, August 4, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment